Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Corcept Therapeutics is conducting an extension study titled ‘An Open-Label Extension Study of the Safety of Relacorilant (CORT125134) in the Treatment of the Signs and Symptoms of Endogenous Cushing Syndrome.’ The study aims to evaluate the long-term safety of relacorilant, a selective glucocorticoid receptor antagonist, in patients with endogenous Cushing syndrome who have completed a prior Corcept-sponsored study. This research is significant as it explores the potential for continued treatment benefits in this patient population.
The intervention being tested is relacorilant, administered as capsules for oral dosing. It is designed to act as a glucocorticoid receptor antagonist, potentially offering therapeutic benefits to patients with Cushing syndrome.
The study follows an interventional design with a single-group model and no masking, focusing primarily on treatment. This straightforward approach allows for the assessment of relacorilant’s safety over an extended period.
Key dates for the study include its start on May 7, 2018, with the last update submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipated completion.
From a market perspective, the continuation of this study could positively influence Corcept Therapeutics’ stock performance by reinforcing investor confidence in the company’s commitment to developing effective treatments for Cushing syndrome. The ongoing research may also position Corcept favorably against competitors in the endocrine disorder treatment market.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.